I-Corps: Novel, collagen-based biomaterial
I-Corps: Novel, collagen-based biomaterial
批准号:
1744808
负责人:
Yujia Xu
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-15 至 2018-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The broader impact of this I-Corps Team project is a new collagen-mimetic material that will lead to the development of safer, cheaper, and customizable products for medical applications. Collagen has applications in medicine, pharmaceuticals, personal care products, food industry, and leather industry. The incidences of transmission of pathogens from animal products have added to the market pressure for safer, non-mammalian sources of collagens. The novel, collagen-mimetic fibrils are expected to be a safe collagen-alternative for many collagen-related applications. These new materials can be designed to cater the needs of specific applications and is potentially more versatile and effective than the traditional collagen products. The potential commercial impact is a new generation of collagen-related biomaterials for skin care, bone and joint health, controlled drug release devices, and wound healing.This I-Corps Team project will identify and establish relationships with potential partners across the medical field and the personal care industry. Collagen has long been sought after for its combination of tensile strength and biocompatibility. The emerging peptide biotechnology raised hope of producing collagen-mimetic peptides that can be a safe, economically viable alternative to collagens extracted from animals. Until recently, however, protein design could not produce peptide materials that adapt to the fibril conformation of natural collagens. This project builds upon the development of the first of such fibril-forming triple helical peptide. The self-assembled collagen-mimetic fibrils have the characteristic axial repeating structure reminiscent of that of the D-period of fibrillar collagens in tissues. The collagen-mimetic fibrils can be used as molecular scaffold to create biomaterials that have the supramolecular structure and the tensile strength comparable to that of natural collagen fibrils. The bottom-up approach makes it possible to customize the materials for specific applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microunfolding of the collagen triple helix, its implications in the fibril assembly of collagen and the triple helix as templates for nanoapplications
-
批准号:1022120
-
项目类别:Continuing Grant
-
资助金额:$36.0万
-
财政年份:2010
-
负责人:Yujia Xu
-
依托单位:
Acquisition of Beckman ProteomeLab XL-I Characterization System
-
批准号:0521709
-
项目类别:Standard Grant
-
资助金额:$37.22万
-
财政年份:2005
-
负责人:Yujia Xu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: